NEW YORK (GenomeWeb News) – Metabolon today announced research collaborations and a licensing agreement aimed at diabetes in Mexico and Latin America.

As part of the multiyear, royalty-based research collaborations, Metabolon's Quantose IR technology will be used in several diabetes prevention studies in Mexico. The licensing deal with Patia Biopharma provides exclusive access in Mexico to Metabolon's prediabetes technology for evaluating insulin resistance in Mexico through Patia and Clinica Ruiz's laboratory network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.